These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 15730114)

  • 1. Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence.
    Raisch DW; Fudala PJ; Saxon AJ; Walsh R; Casadonte P; Ling W; Johnson BA; Malkerneker U; Ordorica P; Williford WO; Sather MR
    J Am Pharm Assoc (2003); 2005; 45(1):23-32. PubMed ID: 15730114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia.
    Thornton JD; Lyvers E; Scott VGG; Dwibedi N
    J Am Pharm Assoc (2003); 2017; 57(2S):S12-S18.e4. PubMed ID: 28163027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
    Green TC; Bratberg J; Irwin AN; Boggis J; Gray M; Leichtling G; Bolivar D; Floyd A; Al-Jammali Z; Arnold J; Hansen R; Hartung D
    Subst Abus; 2022; 43(1):901-905. PubMed ID: 35213293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public attitudes and beliefs about Virginia community pharmacists dispensing and administering naloxone.
    Haggerty LC; Gatewood SS; Goode JKR
    J Am Pharm Assoc (2003); 2018; 58(4S):S73-S77.e1. PubMed ID: 30006189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Independent community pharmacists' attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder.
    Zalmai R; Hill LG; Loera LJ; Mosgrove Q; Brown C
    J Am Pharm Assoc (2003); 2023; 63(5):1558-1565.e4. PubMed ID: 37331654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
    Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
    J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacists' attitudes toward dispensing naloxone and medications for opioid use disorder: A scoping review of the literature.
    Muzyk A; Smothers ZPW; Collins K; MacEachern M; Wu LT
    Subst Abus; 2019; 40(4):476-483. PubMed ID: 31418645
    [No Abstract]   [Full Text] [Related]  

  • 8. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama.
    Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL
    Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First insights into community pharmacy based buprenorphine-naloxone dispensing in Finland.
    Uosukainen H; Bell JS; Laitinen K; Tacke U; Ilomäki J; Turunen JH
    Int J Drug Policy; 2013 Sep; 24(5):492-7. PubMed ID: 23567099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attitudes and perceptions of naloxone dispensing among a sample of Massachusetts community pharmacy technicians.
    Kurian S; Baloy B; Baird J; Burstein D; Xuan Z; Bratberg J; Tapper A; Walley A; Green TC
    J Am Pharm Assoc (2003); 2019; 59(6):824-831. PubMed ID: 31582224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of community pharmacy dispensing fees on the introduction of buprenorphine - naloxone in Australia.
    Winstock AR; Lea T; Ritter A
    Drug Alcohol Rev; 2007 Jul; 26(4):411-6. PubMed ID: 17564877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacists' role in opioid overdose: Kentucky pharmacists' willingness to participate in naloxone dispensing.
    Freeman PR; Goodin A; Troske S; Strahl A; Fallin A; Green TC
    J Am Pharm Assoc (2003); 2017; 57(2S):S28-S33. PubMed ID: 28139459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What predicts medication therapy management completion rates? The role of community pharmacy staff characteristics and beliefs about medication therapy management.
    Adeoye OA; Lake LM; Lourens SG; Morris RE; Snyder ME
    J Am Pharm Assoc (2003); 2018; 58(4S):S7-S15.e5. PubMed ID: 29731422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients.
    DiPaula BA; Menachery E
    J Am Pharm Assoc (2003); 2015; 55(2):187-92. PubMed ID: 25749264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states.
    Green TC; Case P; Fiske H; Baird J; Cabral S; Burstein D; Schwartz V; Potter N; Walley AY; Bratberg J
    J Am Pharm Assoc (2003); 2017; 57(2S):S19-S27.e4. PubMed ID: 28214219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified.
    Nielsen S; Dietze P; Dunlop A; Muhleisen P; Lee N; Taylor D
    Drug Alcohol Rev; 2007 Mar; 26(2):143-51. PubMed ID: 17364849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rural and small metro area naloxone-dispensing pharmacists' attitudes, experiences, and support for a frontline public health pharmacy role to increase naloxone uptake in New York State, 2019.
    Tofighi B; Lekas HM; Williams SZ; Martino D; Blau C; Lewis CF
    J Subst Abuse Treat; 2021 Oct; 129():108372. PubMed ID: 34080543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses.
    Melaragni F; Levy C; Pedrazzi J; Andersen M
    J Am Pharm Assoc (2003); 2019; 59(4):550-554.e2. PubMed ID: 31109812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Community pharmacy services for people with drug problems over two decades in Scotland: Implications for future development.
    Matheson C; Thiruvothiyur M; Robertson H; Bond C
    Int J Drug Policy; 2016 Jan; 27():105-12. PubMed ID: 26723885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Community Pharmacists' Knowledge and Perceptions of Buprenorphine for Patients with Opioid Use Disorder.
    Tutag Lehr V; Nolan C
    J Addict Med; 2023 Jul-Aug 01; 17(4):e224-e231. PubMed ID: 37579094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.